Drug intelligence / Profile preview

GLK-401

Development stage: Unknown
Lead developer: Glaukos
Modality: Small Molecules
Administration: Intravitreal

Overview

**GLK-401** is an intravitreal, bio-erodible sustained release implant developed by Glaukos Corporation for retinal diseases. It delivers a multi-kinase inhibitor locally to the posterior segment of the eye, targeting neovascularization and vascular leakage associated with conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). The implant aims to provide prolonged therapeutic effect while minimizing systemic exposure, and it is currently in Phase 2 clinical development with an open U.S. FDA IND.[1][3][9][10][12]

Other names: GLK-401: IVT Multi-Kinase Inhibitor

Targets

PK (Pyruvate kinase)

Beyond the preview

Go deeper on GLK-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLK-401.

Explore the full profile